• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma

by | Jan 14, 2025 | Uncategorized

Source: CureToday articles Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma. Read More

Combination induces durable responses in advanced multiple myeloma

by | Jan 9, 2025 | Uncategorized

The combination of a talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.“Combination therapy with teclistamab plus talquetamab showed encouraging antitumor...

A Year of Resilience: Looking Back After a Myeloma Diagnosis

by | Jan 7, 2025 | Uncategorized

Source: CureToday articles 2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming experience and a fundraising walk. Read More

Anitocabtagene autoleucel exhibits durable efficacy in high-risk advanced multiple myeloma

by | Jan 2, 2025 | Uncategorized

SAN DIEGO — Anitocabtagene autoleucel exhibited durable efficacy among heavily pretreated patients with high-risk relapsed or refractory multiple myeloma, results of the phase 2 iMMagine-1 study showed.Anitocabtagene autoleucel (Arcellx Inc. and Kite Pharma/Gilead...

Darzalex Regimen May Improve MRD Responses in Multiple Myeloma

by | Dec 21, 2024 | Uncategorized

Source: CureToday articles Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination. Read More

Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey

by | Dec 17, 2024 | Uncategorized

Source: CureToday articles Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®. Read More
« Older Entries
Next Entries »

Recent Content

  • Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome
  • Myeloma Awareness Month and Acknowledging Early Symptoms of The Disease
  • Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis
  • Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis
  • Correction: Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection
  • Genetic Study Sheds Light on Inherited Risk of Multiple Myeloma
  • A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
  • Expert Explains Early Signs, Treatment Advances and Care in Multiple Myeloma
  • Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review
  • Pharmacists Play an Essential Role in Bispecific Therapy for Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT